Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2012
- Total Asset Turnover since 2012
- Price to Book Value (P/BV) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Net revenues1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 14, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 16, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 19, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2013 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of AbbVie Inc. Annual Report.
The price-to-sales ratio exhibited fluctuating behavior over the observed period. Initially, the ratio demonstrated an increasing trend from 2013 to 2014, followed by a moderate increase through 2015. A subsequent decline was noted in 2016, before stabilizing in 2017. A significant surge occurred in 2018, followed by a decrease in 2019. The ratio then experienced a period of relative stability between 2019 and 2021, before increasing steadily from 2021 to 2026.
- Initial Growth (2013-2015)
- From 2013 to 2015, the price-to-sales ratio increased from 3.30 to 4.90. This suggests a growing investor confidence in the company’s ability to generate sales relative to its share price during this period. The increase, while consistent, was not dramatic, indicating a measured positive response.
- Volatility and Stabilization (2016-2017)
- A decrease to 3.83 was observed in 2016, potentially reflecting market adjustments or company-specific events. The ratio then stabilized at approximately 3.84 in 2017, suggesting a temporary equilibrium after the prior year’s decline.
- Significant Peak and Subsequent Dip (2018-2019)
- The ratio experienced a substantial increase in 2018, reaching 6.67, indicating a potentially overvalued stock or heightened investor expectations. This was followed by a notable decrease to 3.58 in 2019, possibly representing a correction or a reassessment of the company’s prospects.
- Recent Increasing Trend (2021-2026)
- From 2021 through 2026, the price-to-sales ratio demonstrated a consistent upward trend, increasing from 4.05 to 6.50. This suggests a strengthening market valuation of the company’s sales generation capabilities. The rate of increase appears to be accelerating in the later years of the period.
The share price and sales per share both generally increased over the period, contributing to the observed fluctuations in the price-to-sales ratio. The ratio’s movements suggest periods of investor optimism, correction, and renewed confidence, reflecting the dynamic interplay between market sentiment and the company’s financial performance.
Comparison to Competitors
| AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | ||||||||||||
| Feb 14, 2025 | ||||||||||||
| Feb 20, 2024 | ||||||||||||
| Feb 17, 2023 | ||||||||||||
| Feb 18, 2022 | ||||||||||||
| Feb 19, 2021 | ||||||||||||
| Feb 21, 2020 | ||||||||||||
| Feb 27, 2019 | ||||||||||||
| Feb 16, 2018 | ||||||||||||
| Feb 17, 2017 | ||||||||||||
| Feb 19, 2016 | ||||||||||||
| Feb 20, 2015 | ||||||||||||
| Feb 21, 2014 | ||||||||||||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
AbbVie Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| AbbVie Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 20, 2026 | ||
| Feb 14, 2025 | ||
| Feb 20, 2024 | ||
| Feb 17, 2023 | ||
| Feb 18, 2022 | ||
| Feb 19, 2021 | ||
| Feb 21, 2020 | ||
| Feb 27, 2019 | ||
| Feb 16, 2018 | ||
| Feb 17, 2017 | ||
| Feb 19, 2016 | ||
| Feb 20, 2015 | ||
| Feb 21, 2014 | ||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
| AbbVie Inc. | Health Care | |
|---|---|---|
| Feb 20, 2026 | ||
| Feb 14, 2025 | ||
| Feb 20, 2024 | ||
| Feb 17, 2023 | ||
| Feb 18, 2022 | ||
| Feb 19, 2021 | ||
| Feb 21, 2020 | ||
| Feb 27, 2019 | ||
| Feb 16, 2018 | ||
| Feb 17, 2017 | ||
| Feb 19, 2016 | ||
| Feb 20, 2015 | ||
| Feb 21, 2014 | ||
| Mar 15, 2013 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).